Literature DB >> 30956228

THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis".

Roberta Pacifici1, Simona Pichini1, Manuela Pellegrini1, Maria Concetta Rotolo1, Raffaele Giorgetti2, Adriano Tagliabracci2, Francesco Paolo Busardò2, Marilyn A Huestis3.   

Abstract

Background "Light cannabis" is a product legally sold in Europe with Δ9-tetrahydrocannabinol (THC) concentration lower than 0.2% and variable cannabidiol (CBD) content. We studied THC and CBD excretion profiles in blood, oral fluid (OF) and urine after smoking one or four light cannabis cigarettes. Methods Blood, OF and urine samples were obtained from six healthy light cannabis consumers after smoking one 1 g cigarette containing 0.16% THC and 5.8% CBD and from six others after smoking four 1 g cigarettes within 4 h. Sample collection began 0.5 and 4.5 h after smoking one or four cigarettes, respectively. Cannabinoid concentrations were quantified by gas chromatography-mass spectrometry (GC-MS). Results At the first collection, the highest THC and CBD concentrations occurred in blood (THC 7.0-10.8 ng/mL; CBD 30.2-56.1 ng/mL) and OF (THC 5.1-15.5 ng/mL; CBD 14.2-28.1 ng/mL); similar results occurred 0.5 h after the last of four cigarettes in blood (THC 14.1-18.2 ng/mL, and CBD 25.6-45.4 ng/mL) and OF (THC 11.2-24.3 ng/mL; CBD 14.4-37.0 ng/mL). The mean OF to blood ratio ranged from 0.6 to 1.2 after one and 0.6 to 1.9 after four light cannabis cigarettes. THC/CBD ratios in blood and OF were never greater than 2. Urinary 11-nor-9-carboxy-THC concentrations peaked 8 h after one and four cigarettes. Conclusions OF was a valuable alternative to blood in monitoring consumption of light cannabis. Blood and OF THC/CBD concentration ratios, never exceeded 2, possibly providing a useful biomarker to identify light cannabis vs illegal higher THC cannabis use, where THC/CBD ratios are generally greater than 10.

Entities:  

Keywords:  blood; light cannabis; oral fluid; urine; variable cannabidiol (CBD); Δ9-tetrahydrocannabinol (THC)

Mesh:

Substances:

Year:  2020        PMID: 30956228     DOI: 10.1515/cclm-2019-0119

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Cannabidiol promotes adipogenesis of human and mouse mesenchymal stem cells via PPARγ by inducing lipogenesis but not lipolysis.

Authors:  Richard C Chang; Chloe S Thangavelu; Erika M Joloya; Angela Kuo; Zhuorui Li; Bruce Blumberg
Journal:  Biochem Pharmacol       Date:  2022-01-10       Impact factor: 5.858

2.  Orally administered cannabidiol does not produce false-positive tests for Δ9 -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000.

Authors:  Danielle McCartney; Richard C Kevin; Anastasia S Suraev; Christopher Irwin; Ronald R Grunstein; Camilla M Hoyos; Iain S McGregor
Journal:  Drug Test Anal       Date:  2021-08-30       Impact factor: 3.234

3.  A rapid assay provides on-site quantification of tetrahydrocannabinol in oral fluid.

Authors:  Hojeong Yu; Hoyeon Lee; Jiyong Cheong; Sang Won Woo; Juhyun Oh; Hyun-Kyung Oh; Jae-Hyun Lee; Hui Zheng; Cesar M Castro; Yeong-Eun Yoo; Min-Gon Kim; Jinwoo Cheon; Ralph Weissleder; Hakho Lee
Journal:  Sci Transl Med       Date:  2021-10-20       Impact factor: 19.319

4.  Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.

Authors:  Dennis J Sholler; Tory R Spindle; Edward J Cone; Elia Goffi; David Kuntz; John M Mitchell; Ruth E Winecker; George E Bigelow; Ronald R Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2022-05-20       Impact factor: 3.220

5.  Using Population Pharmacokinetic Modeling to Estimate Exposure to Δ9-Tetrahydrocannabinol in an Observational Study of Cannabis Smokers in Colorado.

Authors:  Cristina Sempio; L Cinnamon Bidwell; Kent Hutchison; Marilyn A Huestis; Jost Klawitter; Uwe Christians; Thomas K Henthorn
Journal:  Ther Drug Monit       Date:  2021-08-01       Impact factor: 3.118

6.  Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis.

Authors:  Ana Pilar Pérez-Acevedo; Francesco Paolo Busardò; Roberta Pacifici; Giulio Mannocchi; Massimo Gottardi; Lourdes Poyatos; Esther Papaseit; Clara Pérez-Mañá; Soraya Martin; Annagiulia Di Trana; Simona Pichini; Magí Farré
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-12

Review 7.  A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment.

Authors:  Rosario Licitra; Maria Marchese; Valentina Naef; Asahi Ogi; Marco Martinelli; Claudia Kiferle; Baldassare Fronte; Filippo Maria Santorelli
Journal:  Biomedicines       Date:  2022-07-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.